Assessing the validity and clinical meaningfulness of skin pain response (NRS30) assessed using numerical rating scale in hidradenitis suppurativa: Results from the SUNSHINE and SUNRISE trials

J Am Acad Dermatol. 2023 Dec;89(6):1285-1287. doi: 10.1016/j.jaad.2023.07.1035. Epub 2023 Aug 12.

Affiliations

¹ Novartis Pharma Shanghai, Shanghai, China. Electronic address: xiaoling.wei@novartis.com.
² Novartis Pharma AG, Basel, Switzerland.
³ Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
⁴ Novartis Ireland Limited, Dublin, Ireland.

PMID: 37579844
DOI: 10.1016/j.jaad.2023.07.1035

No abstract available

Keywords: HS-related pain; NRS30; acne inversa; hidradenitis suppurativa; pain measurement; secukinumab; validation.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adalimumab
Hidradenitis Suppurativa* / diagnosis
Humans
Pain / etiology
Skin

Substances

Adalimumab